ArticleCureus2026
Phototherapy for Skin of Color in the Biologic Era: A Cross-Sectional Survey of Moroccan Dermatologists' Knowledge and Practice.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Phototherapy remains central to the treatment of inflammatory and pigmentary skin disease and is especially relevant in populations with darker skin phototypes. As biologic and targeted therapies expand, the place of phototherapy in resource-limited settings is uncertain. We assessed the knowledge, perceptions, and practice of Moroccan dermatologists regarding phototherapy and identified barriers to its use. Methods A cross-sectional, self-administered, web-based survey (34 items) was distributed to Moroccan dermatologists via the Moroccan Society of Dermatology network between October and November 2025, covering demographics, access, technical competency, knowledge, prescribing, attitudes toward biologic and targeted therapies, and training needs. Exploratory cross-tabulations (Fisher's exact test) and 95% CIs (Clopper-Pearson method) were computed for the principal proportions. Results Of 53 respondents (91% female, 51% in private practice), 94% had ever prescribed phototherapy, but only 43% (95% CI: 30-58%) had access to a unit. Most respondents rated their knowledge of indications as sufficient or better; however, only 17% (95% CI: 8-30%) identified the guideline-based psoralen plus ultraviolet A risk-monitoring threshold, and 34% (95% CI: 22-48%) identified the recommended minimum age for narrowband ultraviolet B. Most (70%) considered phototherapy to retain a major role alongside biologic and targeted therapies, and a majority reported offering it before escalation in psoriasis (83%), vitiligo (76%), and atopic dermatitis (62%). Access to a phototherapy unit was strongly associated with public or university practice (p < 0.001) and with regular prescribing (p < 0.001). Logistical (79%), institutional (45%), and space-related (38%) barriers predominated; only 36% had received phototherapy training during residency. Conclusions Moroccan dermatologists express strong support for phototherapy and report offering it before biologic and targeted therapies across major indications, but deficits in equipment access, guideline-based knowledge, and postgraduate training represent barriers to optimal practice. These findings highlight the need for further research, including objective competency assessments and clinical outcome studies, to inform strategies for equipment deployment, structured training, and a national phototherapy network.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.